Article Figures & Data
Tables
Characteristic Patients (n) Sex Male 77 Female 274 Age (range, 18–81 y) ≤45 y 98 45 y 253 Histology Papillary microcarcinoma 351 Size ≤5 mm 157 5 mm 194 Structural characteristics Unifocal 252 Multifocal, unilateral 75 Multifocal, bilateral 24 Extrathyroidal extension 14 Neck lymph node status Level VI lymph node metastases (N1a) 20 Cervical metastases (N1b) 13 Distant metastases 1 Risk stratification High risk 20 Low risk 96 Very low risk 235 Classification Site Planar WBS* SPECT/CT† In neck 220 radioiodine-avid foci 263 radioiodine-avid foci 162 residues 159 residues 2 metastases 1 physiologic focus 58 unclear 30 residues 23 metastases 5 physiologic foci Planar WBS occult foci 25 residues 18 metastases Outside neck 28 radioiodine-avid foci 35 radioiodine-avid foci 11 metastases 11 metastases 2 cutaneous contaminations 2 cutaneous contaminations 15 unclear 3 metastases 4 benign disease 8 physiologic foci Planar WBS occult foci 7 metastases During follow-up At surgery Thyroglobulin (ng/mL) Lesions, planar WBS (n) Lesions, SPECT/CT (n) Patient no. Age (y) Sex Clinical diagnosis Size (mm) Focality TNM LN M Risk Hypo rh TSH In neck Outside neck In neck Outside neck 1 59 F STN-i 5 UF T1aN0M0 VL <2.5 1U 1LCL 2 50 F MNG-i 5 UF T1aN0M0 VL Und 2LCL, 1SCL 3 68 M MNG-ni 10 UF T4N0M1 Bone H >10 1U 1PM, 5STM, 4ICL, 1U 1 LCL 1PM, 5STM, 4ICL, 1bone*, 1ABL 4 61 F MNG-i 10 UF T1aN0M0 VL Und 1SML 5 65 F MNG-i 2 UF T1aN0M0 VL Und 1SML 6 43 M STN-ni 10+microfoci MF BL T1aN1bM0 N1b H 3U 3LCL 7 73 F MNG-HD-i 9+2 MF BL T1aN1bM0 L <2.5 1U 1PTL 1ML 8 49 F STN-ni 10+microfoci MF UL T1aN1bM0 L 2.5–5 3U 2SML, 1PTL 1PM (NSCLC) 9 49 F MNG-i 10 UF T1aN0M0 VL <2.5 1SML 10 66 F STN-ni 10 T1aN0M0 L <2.5 1bone* 11 69 F MNG-ni 6+4 MF BL T1aN1bM0 L 5–10 5U 1U 2SML, 2PTL, 1SCL 1bone* 12 60 F MNG-HD-i 4 UF T1aN0M0 VL Und 1LCL 13 35 F GD-i 10 UF T1aN0M0 VL Und 1PTL 14 49 F MNG-ni 10+7 MF BL T1aN0M0 L Und 2U 1SML, 1SCL 15 72 F STN-ni 10 UF T1aN0M0 VL Und 1U 1SCL 16 47 M GD-i 8 UF T1aN0M0 VL <2.5 1LCL, 1SML 17 38 F STN-ni 6 UF T1aN0M0 VL <2.5 2 PTL 18 66 F MNG-ni 4 UF T1aN1bM0 N1b H 2.5–5 2U 4LCL, 1SCL 1ML, 1PM 19 60 F MNG-HD-ni 10+5 MF BL T1aN0M0 L <2.5 1PM 1PM, 1HPL 20 40 M MNG-i 7+3 MF UL T1aN0M0 L Und 1PTL 21 54 F MNG-i 5 UF T1aN0M0 VL Und 1U 1SML 22 47 F GD-i 6 UF T1aN0M0 VL Und 1LCL 23 40 F STN-ni 2.5+microfoci MF UL T1aN1bM0 N1b H 5–10 2† 1LCL, 1PTL 24 43 F MNG-HD-i 6 UF T1aN0M0 VL Und 1U 1SML 25 43 M STN-HD-ni 9+3 MF, UL T1aN1aM0 N1a H Und 1U 1LCL 26 31 F STN-HD-ni 10 UF T1aN1bM0 N1b H >10 1U 2LCL 27 54 F MNG-i 7 UF T1aN0M0 VL Und 1U 1ML ↵* Ischium in patient 3, rib in patient 10, and spine in patient 11.
↵† Wrongly classified as residues.
Clinical diagnosis: HD = Hashimoto thyroiditis; GD = Graves disease; i = incidental; MNG = multinodular goiter; ni = not incidental; STN = solitary thyroid nodule.
Focality: BL = bilateral; MF = multifocal; UF = unifocal; UL = unilateral.
LN = lymph node metastases; M = distant metastases.
Risk: H = at high risk; L = at low risk; VL = at very low risk.
Hypothyroidal (hypo) and recombinant human (rh) TSH: und = undetectable.
Lesions: ABL = abdominal LN; HPL = hilar pulmonary LN; ICL = inguinocrural LN; LCL = laterocervical LN; ML = mediastinal LN; NSCLC = non–small cell lung cancer; PM = pulmonary metastases; PTL = paratracheal LN; SCL = supraclavicular LN; SML = submandibular LN; STM = soft-tissue metastases; U = unclear.
Jump to section
Related Articles
Cited By...
- No citing articles found.